Biomm S.A Market Cap ($159.23 Million)
Market Cap & Net Worth: Biomm S.A (BIOM3)
Biomm S.A market cap. Biomm S.A (SA:BIOM3) has a market capitalization of $159.23 Million (R$811.47 Million) as of November 8, 2026. Listed on the SA stock exchange, this Brazil-based company holds position #17182 globally and #165 in its home market, demonstrating a 11.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomm S.A's stock price R$5.93 by its total outstanding shares 136841532 (136.84 Million). Also see Biomm S.A cash conversion from operations for how efficiently the company converts equity into cash flow.
Biomm S.A Market Cap History (2015–2026)
Biomm S.A market cap history from 2015 to 2026. Data shows change from $150.36 Million to $159.23 Million (-0.96% CAGR). Check Biomm S.A (BIOM3) share price today for real-time trading data and today's change.
Biomm S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomm S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Biomm S.A to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.00x
Biomm S.A's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $255.08 Million | $103.00K | -$38.13 Million | 2476.53x | N/A |
| 2018 | $219.37 Million | $1.57 Million | -$42.56 Million | 140.08x | N/A |
| 2019 | $332.95 Million | $8.94 Million | -$55.81 Million | 37.23x | N/A |
| 2020 | $435.25 Million | $58.67 Million | -$70.77 Million | 7.42x | N/A |
| 2021 | $348.52 Million | $107.09 Million | -$80.26 Million | 3.25x | N/A |
| 2022 | $182.32 Million | $104.95 Million | -$92.56 Million | 1.74x | N/A |
| 2023 | $155.20 Million | $118.19 Million | -$81.14 Million | 1.31x | N/A |
| 2024 | $286.23 Million | $142.91 Million | -$77.24 Million | 2.00x | N/A |
Competitor Companies of BIOM3 by Market Capitalization
Companies near Biomm S.A in the global market cap rankings as of November 8, 2026. Also see Biomm S.A total assets for a full breakdown of the balance sheet.
Key companies related to Biomm S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Biomm S.A (2015–2026)
Market capitalization of Biomm S.A from 2015 to today. Between 2015 and today, Biomm S.A's market cap moved from $150.36 Million to $ 159.23 Million, with a yearly change of -0.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | R$159.23 Million | -17.87% |
| 2025 | R$193.86 Million | -32.27% |
| 2024 | R$286.23 Million | +84.43% |
| 2023 | R$155.20 Million | -14.87% |
| 2022 | R$182.32 Million | -47.69% |
| 2021 | R$348.52 Million | -19.93% |
| 2020 | R$435.25 Million | +30.73% |
| 2019 | R$332.95 Million | +51.77% |
| 2018 | R$219.37 Million | -14.00% |
| 2017 | R$255.08 Million | +47.29% |
| 2016 | R$173.19 Million | +15.18% |
| 2015 | R$150.36 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Biomm S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $159.23 Million USD |
| MoneyControl | $159.23 Million USD |
| MarketWatch | $159.23 Million USD |
| marketcap.company | $159.23 Million USD |
| Reuters | $159.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomm S.A
Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-st… Read more